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Glucose-6-Phosphate–Mediated Activation of Liver
Glycogen Synthase Plays a Key Role in Hepatic
Glycogen Synthesis
Alexander von Wilamowitz-Moellendorff,1 Roger W. Hunter,1 Mar García-Rocha,2 Li Kang,3
Iliana López-Soldado,2 Louise Lantier,3 Kashyap Patel,1 Mark W. Peggie,1 Carlos Martínez-Pons,2
Martin Voss,1 Joaquim Calbó,2 Patricia T.W. Cohen,1 David H. Wasserman,3 Joan J. Guinovart,2
and Kei Sakamoto1
The liver responds to an increase in blood glucose levels in the
postprandial state by uptake of glucose and conversion to
glycogen. Liver glycogen synthase (GYS2), a key enzyme in
glycogen synthesis, is controlled by a complex interplay between
the allosteric activator glucose-6-phosphate (G6P) and reversible
phosphorylation through glycogen synthase kinase-3 and the
glycogen-associated form of protein phosphatase 1. Here, we
initially performed mutagenesis analysis and identified a key
residue (Arg582) required for activation of GYS2 by G6P. We then
used GYS2 Arg582Ala knockin (+/R582A) mice in which G6P-
mediated GYS2 activation had been profoundly impaired (60–70%),
while sparing regulation through reversible phosphorylation.
R582A mutant–expressing hepatocytes showed significantly re-
duced glycogen synthesis with glucose and insulin or glucokinase
activator, which resulted in channeling glucose/G6P toward glycol-
ysis and lipid synthesis. GYS2+/R582A mice were modestly glucose
intolerant and displayed significantly reduced glycogen accumula-
tion with feeding or glucose load in vivo. These data show that
G6P-mediated activation of GYS2 plays a key role in controlling
glycogen synthesis and hepatic glucose-G6P flux control and thus
whole-body glucose homeostasis. Diabetes 62:4070–4082, 2013
The liver plays a central role in maintaining bloodglucose homeostasis by uptake of glucose in thepostprandial state and conversion to glycogenand triglyceride and by production of glucose in
the postabsorptive state by glycogenolysis and gluconeo-
genesis (1,2). Defects in the mechanisms by which glucose
and insulin regulate hepatic glycogen metabolism disrupt
blood glucose homeostasis and are highly associated with
metabolic disorders such as type 2 diabetes (3) and gly-
cogen storage disease (4,5).
The rate-limiting enzyme for glycogen synthesis is gly-
cogen synthase (GS), which catalyzes the addition of
a-1,4–linked glucose units from uridine diphosphate (UDP)
glucose to a nascent glycogen chain (5,6). In mammals,
there are two GS isoforms: muscle GS (encoded by GYS1),
which is abundantly expressed in skeletal and cardiac
muscles, and the liver-restricted isoform (encoded by
GYS2) (7). Activity of both isoforms is regulated by phos-
phorylation at multiple sites and allosteric effectors of
which glucose-6-phosphate (G6P) is the most important
(5,8). G6P functions as an allosteric activator of the
phosphorylated enzyme, and even hyperphosphorylated
GS can be fully activated by saturating concentrations of
G6P in cell-free assays. Dephosphorylation activates GS
and also results in significant changes in kinetic properties,
decreasing the Km for the substrate UDP glucose and the
A0.5 for G6P (9,10). Despite decades of intensive research,
the relative importance of these two regulatory mecha-
nisms, particularly the contribution of allosteric regulation
to the control of GS and glycogen storage in liver in vivo,
is not established. This is mainly due to the complex in-
terplay between multiple phosphorylation sites and al-
losteric effectors and most notably the lack of robust
experimental tools.
A well-defined pathway has been established by which
insulin is thought to stimulate GS and the deposition of
glycogen in tissues. Activated protein kinase B (PKB)
phosphorylates and inhibits GS kinase 3 (GSK3), which is
itself a negative regulator of GS through phosphorylation
at COOH-terminal residues (11). To determine the role that
phospho-dependent regulation of GS by GSK3 plays in
controlling glycogen metabolism, we previously generated
knockin mice expressing constitutively active mutants of
GSK3 in which the PKB phosphorylation sites on GSK3a
(S21) and GSK3b (S9) were substituted by Ala (12). In
addition, Patel and colleagues (13,14) have recently gen-
erated mice in which GSK3a or GSK3b was specifically
ablated in liver. Strikingly, all GSK3 knockin and condi-
tional GSK3 knockout animals displayed normal levels of
liver glycogen upon feeding.
In liver, elevated intracellular glucose levels have been
proposed to stimulate GYS2 by a mechanism involving
a liver-specific glycogen-targeting subunit, GL (2). GYS2 is
dephosphorylated and activated by protein phosphatase-1
(PP1) complexed with GL. GL also interacts with the acti-
vated form of glycogen phosphorylase (GPa), which
antagonizes activation of GS through PP1-GL. When blood
glucose levels are elevated, glucose binds to hepatic GPa
and stabilizes the enzyme in the inactive conformation
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(GPb). Glycogenolysis is switched off, and inhibition of
PP1-GL is blocked, allowing PP1-GL to dephosphorylate
and activate GS and promote glycogen deposition in the
liver. Kelsall et al. (15) reported that binding between GL
and GP could be disrupted by a single point mutation
(GL
Y284→F) and generated a knockin mouse model carry-
ing this mutation to examine the physiological role of this
allosteric interaction in hepatic glycogen metabolism in
vivo (16). Although GYS2 activity was significantly in-
creased after a short fast, liver glycogen levels in fed
GL
Y284F mice were comparable with those observed in
wild-type (WT) controls (15,16).
Based on these studies (12–14,16) and early observa-
tions demonstrating a tight linear relationship between
intracellular concentrations of G6P and GYS2 activation in
hepatocytes (8,17), we hypothesized that allosteric acti-
vation of GYS2 by G6P plays a key role in regulating hepatic
glycogen synthesis. In the current study, we identified res-
idues essential for G6P-mediated activation of GYS2 and
generated a knockin mouse expressing a G6P-insensitive
GYS2 mutant. Here, we report genetic evidence that G6P-
mediated allosteric activation of GYS2 plays an important
role in hepatic glycogen synthesis.
RESEARCH DESIGN AND METHODS
Animal studies were approved by the University of Dundee ethics committee
and performed under a U.K. Home Office project license or the Barcelona
Science Park’s Animal Experimentation Committee and in accordance with
the European Community Council Directive and the National Institute of
Health guidelines for the care and use of laboratory animals or the Vanderbilt
University Animal Care and Use Committee. C57BL/6J GYS2+/R582A knockin mice
were generated by TaconicArtemis. GLY284F/Y284F knockin mice were gener-
ated as previously described (16). GYS2 knockout mice [Gys2tm1a(KOMP)Wtsi]
were generated by the Sanger Institute Mouse Genetics Project and have been
backcrossed to the C57BL/6J strain for more than eight generations. All ani-
mals were maintained on a 12/12-h light/dark cycle and had free access to
standard chow and water. Animals were 8–12 weeks old at the time of the
experiment unless otherwise indicated.
GS assay. GS activity in muscle and liver lysates was measured by a modifi-
cation of the method of Thomas et al. (18) with or without saturating G6P and
1.5 mmol/L (muscle) or 5 mmol/L (liver) UDP glucose.
Glucose utilization. After overnight incubation, mouse hepatocytes were
transferred to M199 medium containing 5.5 mmol/L glucose and 20 mmol/L
HEPES and rested for 2 h prior to labeling with 25 mmol/L glucose containing
0.2 mCi/mmol [14C(U)]D-glucose in the presence of 10 nmol/L insulin or 10
mmol/L Cpd A for 2 h. [14C]-CO2 was released by acidification of conditioned
media and trapped in 1 mol/L benzethonium hydroxide. Cell monolayers were
washed and scrapped into ice-cold PBS and lipids extracted according to the
method of Bligh and Dyer (19). Extracts were applied to Partisil K6 silica TLC
plates and neutral lipids resolved in petroleum ether:diethyl ether:acetic acid
(70:30:1). Lipids were stained with iodine vapor and selected species scraped
into scintillation vials and eluted with 1:1 ethanol:TritonX-100. Glycogen was
recovered from the particulate material remaining after the Bligh and Dyer
extraction by digestion in 30% (w/v) KOH and precipitation with 66% ethanol.
[14C] incorporation was determined by scintillation counting.
Euglycemic-hyperinsulinemic clamp. Catheters were implanted into the
carotid artery and jugular vein of mice for sampling and infusions, respectively,
5 days before the study as previously described (20). Experimental details are
described in the Supplementary Data.
Statistics. Data are expressed as means 6 SE. Statistical analysis was per-
formed using two-way ANOVA or one-way ANOVA using Tukey or Dunn post
hoc tests for multiple comparisons where appropriate. Differences between
groups were considered statistically significant when P , 0.05.
RESULTS
Identification of G6P-resistant GYS2 mutant(s) by
targeted mutagenesis. To identify residues essential for
the activation of GS by G6P, we generated a series of GYS2
mutants containing Ala substitutions in the basic region
identified as critical for G6P sensitivity in the yeast homolog,
Gsy2p (Fig. 1A) (22). Human embryonic kidney (HEK) 293
cells were cotransfected with untagged GYS2 constructs
and the glycogenesis primer, glycogenin, which enhances
soluble expression (23). Immunoblotting confirmed the
absence of endogenous GYS2 in these cells and near-equal
expression and phosphorylation for all mutants (Fig. 1B).
When lysates were assayed for glucosyltransferase activity,
addition of saturating G6P to WT GYS2 resulted in ;30-fold
increase in activity. Taking this into account, the activity of
R582A, R586A, and R588A was essentially unaffected by
G6P, while the remaining mutants either displayed mark-
edly elevated G6P-independent activity or were normally
activated by G6P (Fig. 1B).
Ectopically expressed GS in HEK 293 cells is heavily
phosphorylated and essentially inactive without G6P (Fig. 1B).
To ensure that the G6P-insensitive GYS2 mutants were not
catalytically inactive, we dephosphorylated isolated pro-
tein in vitro with PP1g, which renders the enzymes G6P
independent. WT and mutant GYS2 were efficiently
dephosphorylated by PP1g (Fig. 1C). As expected, de-
phosphorylation of WT GYS2 was associated with a ro-
bust increase in GS activity without G6P, which was
ablated in the presence of the PP1 inhibitor, microcystin.
R582A and R586A were similarly activated by dephos-
phorylation, whereas R588A was activated to ;50% of WT
(Fig. 1C). These results demonstrate that R582 and R586
are essential for allosteric activation of GYS2 by G6P and
can be substituted for Ala to generate mutant enzymes that
are resistant to G6P yet retain normal expression, phos-
phorylation, and phospho-dependent activity.
The crystal structure of yeast Gsy2p in complex with G6P
has been solved, which revealed that His286, Lys90, His500,
Arg583, and Arg587 make important side chain interactions
with G6P (24). The latter two residues, Arg583/587, corre-
spond with Arg582/586 in mouse GYS2 and mediate essential
interactions with the phosphate group of G6P.
G6P-insensitive GYS2 mutant exhibits markedly
lower glycogen accumulation in hepatocytes. To as-
sess the role of G6P-mediated activation of GYS2 in a cel-
lular context, we introduced WT or R582A GYS2 constructs
using adenovirus into primary hepatocytes isolated from
GYS22/2mice. In parallel, GYS2 constructs were coinfected
with adenovirus encoding green fluorescent protein (GFP)
(negative control) or GFP fused with protein targeting to
glycogen (PTG) in order to promote glycogen accumula-
tion by dephosphorylation/activation of GYS2 (25,26). It
was anticipated that PTG-driven glycogen accumulation
would be unaffected in R582A-expressing hepatocytes. We
observed that expression of R582A was lower when the
same amount (multiplicity of infection = 8) of adenovirus
was used, and thus we used a higher amount (multiplicity
of infection = 16) of R582A-encoding adenovirus to have
expression similar to that of WT. Both WT and R582A
displayed negligible G6P-independent activity due to high
basal phosphorylation (Fig. 2A). Glucokinase (GK) ex-
pression was comparable between WT- and R582A-
expressed hepatocytes (Supplementary Fig. 5). WT activity
was robustly increased by G6P, whereas R582A was un-
affected (Fig. 2A). PTG coexpression reduced phosphor-
ylation of both WT and R582A, which was associated
with enhanced G6P-independent activity. However, G6P-
independent activity of R582A only reached ;30% of WT
(Fig. 2A). GYS2-null hepatocytes contained only trace
levels of glycogen, which was unaffected by hyperglyce-
mic culture (Fig. 2B). Expression of WT, but not R582A,
promoted a modest accumulation of glycogen in high
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FIG. 1. Mutagenesis and biochemical analysis to identify G6P-insensitive GYS2 mutants. A: Domain structure of GYS2 and sequence alignment of
the G6P binding site, catalytic domain (E-X7-E, two catalytic glutamic acid residues separated by 7 amino acids), and NH2- and COOH-terminal
phosphorylation sites. UniProt accession numbers are indicated in brackets. B: Arg residues located in the G6P-binding region shown in A were
mutated individually either Ala or Glu. Constructs expressing WT or mutant GYS2 were cotransfected with GST-tagged glycogenin in HEK293
cells. Cell lysates were immunoblotted with the indicated antibodies or assayed for GS activity 6 G6P (10 mmol/L). Results are representative of
three independent experiments (n = 2/condition). C: Equal quantities of purified GYS2 mutants were dephosphorylated in vitro using PP1g.
Microcystin LR was used as a negative control. Mock and PP1g-treated GYS2 mutants were assayed for GS activity 6 G6P and immunoblotted to
confirm equal loading and dephosphorylation of critical regulatory sites. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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glucose. With coexpression of PTG, there was a profound
increase in glycogen content in WT-expressing hepatocytes
and also, albeit to a lesser extent, in R582A-expressing cells
(Fig. 2C). In addition, the levels of glycogen were associated
with the degree of G6P-independent GS activity promoted
by dephosphorylation (Fig. 2A).
Localization of exogenously expressed GYS2 in GYS22/2
hepatocytes was analyzed by immunofluorescence. WT GYS2
FIG. 2. Adenoviral overexpression and dephosphorylation of GYS2 R582A in primary hepatocytes from GYS2 knockout mice. A: Primary he-
patocytes were isolated from GYS22/2mice and coinfected with adenovirus (Ad) expressing GYS2 WT or GYS2 R582A and PTG-GFP or GFP for 2 h
followed by media replacement and overnight incubation. Subsequently, cells were incubated with or without 25 mmol/L glucose for 6 h prior to
harvesting. Lysates were assayed for GS activity 6 G6P (7.1 mmol/L) (n = 2–3 from three independent experiments) and subjected to immuno-
blotting using the indicated antibodies. Representative immunoblots shown from three independent experiments. *P < 0.05 respective (2 or
+G6P) GYS2 WT (+PTG) vs. GYS2 R582A (+PTG) (n = 3). B and C: Glycogen levels in primary hepatocytes after coinfection with Ad-GYS2 and Ad-
GFP (B) or Ad-PTG (C). #P< 0.05 respective (0 mmol/L or 25 mmol/L glucose) non-GYS2 infection vs. WT or R582A. *P< 0.05 respective (0 mmol/L
or 25 mmol/L glucose) WT vs. R582A (n = 4). D: Hepatocytes were seeded on collagen-coated glass coverslips and incubated with 25 mmol/L glucose
for 6 h, followed by fixing in 4% paraformaldehyde, and stained for total GYS2 and GFP. Nuclei are stained using Hoechst 33342. Confocal images
were taken with a Leica SP2 microscope using a 363 objective without confocal magnification. Results are representative of three independent
experiments (n = 3/condition). The scale bar represents 10 mm. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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FIG. 3. Targeting strategy used to generate GYS2R582A knockin mice, expression and activity of GYS2, liver glycogen levels, and expression of key
glycogen-associated and metabolic proteins in GYS2+/+, GYS2+/R582A, and GYS2R582A/R582A mice. A: Diagram showing the endogenous Gys2 allele, the
targeting knockin construct, the targeted allele with neomycin selection cassette (NEO) still present, and the targeted allele with NEO removed by
Flp recombinase. The gray boxes represent exons (13–16), and the gray triangles represent the flippase recombination target sites. The knockin
allele containing the R582A mutation in exon 14 is illustrated as a black rectangle. B: Genomic DNA isolated from targeted embryonic stem cells
from the indicated genotypes was digested with NsiI or Pf1FI and subjected to Southern blot analysis with the corresponding DNA probes. C:
Genomic DNA isolated from mouse ear biopsies was subjected to PCR analysis. The WT allele produces a 244 bp DNA fragment, while the knockin
allele produces a 362 bp fragment. D: Equal amounts of liver lysate from the indicated genotypes were immunoblotted for total GYS2, and represen-
tative short and long film exposures are shown. Extracellular signal–related kinase (ERK)1/2 was used as a loading control (n = 4–6/group). E: GYS2
expression in liver was quantified by immunoblotting using a Li-COR Odyssey infrared imaging system and normalized to glyceraldehyde-3-phosphate
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localized to defined structures most likely associated with
sites of active glycogen synthesis. In contrast, R582A
showed a disperse localization throughout the cytoplasm
(Fig. 2D), likely due to the absence of glycogen as pre-
viously suggested (27,28). When GYS22/2 hepatocytes were
coinfected with PTG, WT GYS2 and PTG colocalized to the
same structures. Strikingly, under these conditions
R582A was also recruited toward defined structures to-
gether with PTG.
Generation and characterization of G6P-insensitive
GYS2 knockin mice. For further characterization of the
roles that allosteric activation of GYS2 by G6P plays in he-
patic glycogen metabolism and glucose homeostasis in vivo,
a knockin mouse (Arg582→Ala) was generated (Fig. 3A–C).
GYS2R582A/R582A mice displayed normal growth curves (3–15
weeks of age) in both males and females (Supplementary
Fig. 1A).
Unexpectedly, immunoblotting of liver extracts re-
vealed that GYS2 expression was markedly reduced in
GYS2R582A/R582A and modestly in GYS2+/R582A mice
compared with GYS2+/+ by 93% and 27%, respectively
(Fig. 3D and E). Gys2 mRNA levels were unaffected,
which excludes the possibility of hypomorphism from the
R582A knockin allele (Fig. 3F). For assessment of whether
reduced GYS2 expression in GYS2+/R582A mice originated
from the WT or R582A knockin allele, GS activity in
liver extracts from all three genotypes was measured
with or without G6P. In GYS2+/R582A mice, G6P-dependent
activity was significantly reduced (67%) compared with
that of WT, while the GS activity ratio (2/+G6P) was
comparable. In GYS2R582A/R582A mice, only residual GS
activity was detected. Comparing the magnitude of de-
crease in GYS2 expression (27%) with that of G6P-
dependent GS activity (67%) in GYS2+/R582A relative to
GYS2+/+ suggests that the knockin allele was signifi-
cantly expressed at the protein level in GYS2+/R582A mice
(Fig. 3G).
We next measured liver glycogen levels in fed mice and
observed that there was no significant difference between
GYS2+/+ and GYS2+/R582A mice, while glycogen levels
were drastically reduced (96%) in GYS2R582A/R582A mice (Fig.
3H). Periodic acid Schiff staining of liver sections also
confirmed similar hepatic glycogen content between
GYS2+/+and GYS2+/R582A and the near absence of glycogen in
fed GYS2R582A/R582A hepatocytes (Fig. 3I).
It is possible that the near absence of hepatic glycogen
in GYS2R582A/R582A mice globally affected expression or
stability of glycogen-interacting proteins. Interestingly,
immunoblot analysis revealed that key glycosome proteins
(29) such as glycogen debranching enzyme (AGL), glycogenin,
glycogen phosphorylase (GP), and starch-binding domain–
containing protein 1 (STBD1) were reduced in GYS2R582A/R582A
mice in both fed and fasted states (Fig. 3J). In contrast,
other key metabolic proteins mediating glucose trans-
port (GLUT2), glucose phosphorylation/dephosphorylation
(GK/G6Pase), or gluconeogenesis (FBP1 and PEPCK) were
detected in similar quantities (Fig. 3J). Thus, the loss of
glycogen might have affected the levels of glycogen-bound
proteins, while other proteins involved in liver glucose
metabolism were unchanged.
Glucose utilization and metabolic adaptations in
primary hepatocytes carrying GYS2 R582A mutation.
For determination of the physiological consequence of re-
duced G6P-mediated activation or hepatic GYS2 deficiency
on glucose metabolism/flux, glucose utilization by primary
hepatocytes was estimated using [14C(U)]glucose labeling
with or without insulin or GK-activator (CpdA). CpdA was
used to promote phosphorylation of glucose and thereby
raise [G6P]i. GYS2 expression was marginally reduced (10–
20%) in GYS2+/R582A hepatocytes compared with GYS2+/+
cells, while GYS2 expression in GYS2R582A/R582A hepatocytes
was negligible (Fig. 4A). Likewise, GP expression was se-
lectively reduced in GYS2R582A/R582A hepatocytes (Fig. 4A), as
observed in liver lysates (Fig. 3J). Insulin, but not CpdA,
stimulated phosphorylation of PKB and GSK3a/b in all geno-
types to a similar extent. Unstimulated hepatocytes from
GYS2+/+ and GYS2+/R582A mice exhibited low levels of [14C
(U)]glucose incorporation into glycogen, whereas only
trace labeling was detected in GYS2R582A/R582A he-
patocytes (Fig. 4B). Glucose oxidation was significantly
increased in resting GYS2R582A/R582A hepatocytes as well
as [14C] incorporation into triglyceride (Fig. 4C and D).
Insulin modestly but significantly increased [14C]glucose
incorporation into glycogen in hepatocytes from GYS2+/+
(2.2-fold) and GYS2+/R582A (1.5-fold), but no increase
was observed in GYS2R582A/R582A hepatocytes. Treatment of
primary hepatocytes with CpdA resulted in a robust increase
in [14C]glucose incorporation into glycogen in GYS2+/+ he-
patocytes. Although CpdA significantly stimulated glycogen
synthesis (3.5-fold) in GYS2+/R582A, absolute rates of synthesis
were markedly lower (71%) compared with GYS2+/+ he-
patocytes. GYS2R582A/R582A hepatocytes failed to ac-
cumulate detectable levels of glycogen even with CpdA
(Fig. 4B). Taken together, these results show that primary
hepatocytes isolated from GYS2+/R582A mice exhibit a
significantly impaired ability to synthesize glycogen, which
was more pronounced when [G6P]i was raised by CpdA.
Moreover, hypomorphic GYS2R582A/R582A hepatocytes, in-
capable of accumulating glycogen, showed an altered glu-
cose flux favoring lipogenesis. This was corroborated
by significantly elevated liver triglyceride in fed GYS2R582A/R582A
mice (Fig. 4E). Young (2–3 months) GYS2R582A/R582A mice
showed a significant increase in liver triglyceride levels
(16.9 6 2.0 mg/g tissue) compared with GYS2+/+ (11.0 6 1.8
mg/g). Older (6 months) GYS2+/R582A (20.5 6 2.0 mg/g) and
GYS2R582A/R582A mice (24.3 6 2.3 mg/g) had significantly
higher levels of triglycerides compared with both young
mice of the same genotype and GYS2+/+ (Fig. 4E).
Reduced G6P-dependent GYS2 activation causes
impaired hepatic glycogen synthesis after glucose
administration or refeeding. To establish the impact of
reduced G6P-dependent activity or deficiency of GYS2 in
hepatic glycogen synthesis and glucose handling, we per-
formed a glucose tolerance test and monitored the rate of
hepatic glycogen accumulation after glucose injection. Blood
glucose and plasma insulin levels were similar in fed or
dehydrogenase (GAPDH). *P < 0.05 GYS2+/+ vs. other genotypes; #P < 0.05 GYS2+/R582A vs. GYS2R582A/R582A (n = 6/group). F: Total mRNA was
isolated from liver of ad libitum fed and overnight fasted mice and Gys2 mRNA quantified by qPCR. Data were normalized to Gys2 mRNA levels in
ad libitum–fed GYS2+/+ mice. *P < 0.05 fed vs. fasted (n = 6/group). G: GS activity was measured in liver lysates from ad libitum–fed mice 6 10
mmol/L G6P (n = 6/group). H: Glycogen levels were determined in fed (ad libitum) and fasted (6 or 16 h) liver samples (n = 4–8/group). I: Periodic
acid Schiff staining of paraffin-embedded liver sections from ad libitum–fed and fasted mice. Sections were counterstained for hematoxylin-eosin
(n = 3–6/group). J: Liver lysate from ad libitum–fed and overnight fasted mice was immunoblotted using the indicated antibodies (n = 6). GAPDH
was used as a loading control. Representative immunoblots of three independent experiments are shown.
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overnight fasted mice among all genotypes (Supplementary
Fig. 3). Interestingly, after a short fast (6 h) prior to glucose
administration, blood glucose in GYS2R582A/R582A mice was
significantly reduced (7.6 mmol/L) compared with GYS2+/+
(10.4 mmol/L) and GYS2+/R582A (10.2 mmol/L) animals
(Fig. 5A). Injection of glucose elevated blood glucose to
similar absolute levels in all genotypes. However, relative
to fasting blood glucose, GYS2R582A/R582A mice displayed
a significantly higher fold increase between 15 and 60 min
after glucose administration (Fig. 5A). Calculation of area
under the curve (AUC) revealed that there was a moderate
but significant glucose intolerance observed in GYS2+/R582A
and GYS2R582A/R582A animals (Fig. 5B). However, it should
be noted that the kinetics of blood glucose profile during
GTT are similar among genotypes, and the differences in
AUC observed are unlikely to be a consequence of glu-
cose handling; rather, they are likely to be due to differ-
ences in basal glucose levels. Nonetheless, for assessment
FIG. 4. Glucose utilization in primary hepatocytes isolated from GYS2+/+, GYS2+/R582A, and GYS2R582A/R582A mice. A–D: Primary hepatocytes were
isolated from fasted mice and incubated overnight in low glucose (5.5 mmol/L). Medium was changed to 25 mmol/L glucose containing [14C(U)]
glucose, and cells were treated with or without insulin (10 nmol/L) or GK activator (10 mmol/L) for 2 h. [14C]glucose incorporation into CO2,
glycogen, and lipid was determined as described in RESEARCH DESIGN AND METHODS. #P < 0.05 GYS2+/+ vs. other genotypes; *P < 0.05 untreated vs.
insulin or GK activator (n = 4/group). A: Immunoblots of cell lysates from hepatocytes treated as described above in the absence of tracer. B: [14C]
glucose incorporation into glycogen. C: Production of [14C]CO2. D: [
14C]glucose incorporation into triglycerides. E: Liver triglyceride levels from
ad libitum–fed mice of 2–3 and 6 months of age. #P < 0.05 GYS2+/+ vs. other genotypes (n = 6–10/group). GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
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FIG. 5. Glycogen accumulation in GYS2+/+, GYS2+/R582A, and GYS2R582A/R582A mice after bolus glucose injection and refeeding. A: Glucose tolerance
testing of GYS2+/+, GYS2+/R582A, and GYS2R582A/R582A mice was performed as described in RESEARCH DESIGN AND METHODS (n = 5–7/group). B: AUC for
the data in A was calculated using fasting blood glucose levels as baseline. Results are expressed in arbitrary units (AU) and are representative of
three independent experiments. *P < 0.05 GYS2+/+ vs. other genotypes; #P < 0.05 GYS2+/R582A vs. GYS2R582A/R582A (n = 5–7/group). C–H: GYS2+/+,
GYS2+/R582A, and GYS2R582A/R582A mice were fasted for 16 h, followed by administration of glucose (2 mg/g body wt i.p.). Mice were killed at the in-
dicated time points postinjection and analyzed as follows. C: Liver glycogen levels. *P < 0.05 GYS2+/+ vs. other genotype (n = 3–6/group). D: Plasma
lactate levels. *P < 0.05 vs. fasted; #P < 0.05 GYS2+/+ vs. other genotypes (n = 6/group). E: Liver G6P levels. *P < 0.05 vs. fasted; #P < 0.05
GYS2+/+ vs. other genotypes (n = 3–6/group). F: PKBb was immunoprecipitated from liver lysates and assayed for phosphotransferase activity.
*P< 0.05 vs. fasted (n = 6/group). G and H: GS activity was measured in liver lysates6 10 mmol/L G6P and are presented as total GS activity (G)
or the2/+G6P ratio (H). *P< 0.05 vs. fasted (n = 6/group). I–N: GYS2+/R582A and GYS2+/+ mice were fasted overnight followed by 1 h with free access to
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of whether this was associated with impaired hepatic gly-
cogen synthesis, glycogen content was measured at mul-
tiple time points over 2 h after glucose injection. Hepatic
glycogen was reduced to similar levels after an overnight fast
in GYS2+/+ and GYS2+/R582A mice and was essentially absent
in GYS2R582A/R582A (Fig. 5C). Postinjection, recovery of
liver glycogen was significantly blunted in GYS2+/R582A
mice compared with WT, whereas there was no detectable
increase in GYS2R582A/R582A animals. Plasma lactate levels
were significantly increased in GYS2R582A/R582A animals
challenged with glucose (Fig. 5D), most likely due to in-
creased glucose flux to glycolysis. Muscle glycogen levels
significantly decreased (;30%) after an overnight fasting
(A.v.W.-M., K.S., unpublished observations), and glucose
injection did not cause a significant increase in glycogen
content in any of the genotypes up to 2 h postinjection
(Supplementary Fig. 6). Hepatic [G6P] was identical in both
fasted and glucose challenged GYS2+/+ and GYS2+/R582A
mice; however, it was significantly depressed in fasted
GYS2R582A/R582A mice and was not changed in response to
elevated blood glucose (Fig. 5E). These observed differ-
ences were not due to impaired insulin signaling, as PKBb
activity was similarly increased 30 min after glucose chal-
lenge in GYS2+/+ and GYS2+/R582A mice (Fig. 5F). Moreover,
GYS2 phosphorylation/activity was similar at rest and 30
min post–glucose injection, although G6P-dependent GS
activity in GYS2+/R582A mice was significantly lower in
both fasted and post–glucose injection states compared
with GYS2+/+ mice (Fig. 5G). Collectively, these results
demonstrate that impaired hepatic glycogen synthesis in
GYS2+/R582A mice is not due to changes in insulin signaling,
G6P-independent/phosphorylation-dependent GS activity,
or reduced cellular [G6P].
To verify the above results in an alternative physiological
setting, we measured hepatic glycogen levels in response to
refeeding after an overnight fast. Refeeding for 1 h resulted
FIG. 5. Continued.
food (refed) or not (fasted). Mice were killed and analyzed as follows. *P < 0.05 vs. fasted; #P < 0.05 GYS2+/+ vs. other genotypes (n = 5–7/group).
I: Blood glucose levels. J: PKBb kinase activity was measured in liver immunoprecipitates. K: Liver lysates were immunoblotted using the indicated
antibodies. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. Results are representative of two independent
experiments performed with tissues from four mice. L and M: GS activity was measured in liver lysates 6 10 mmol/L G6P and is presented as total
GS activity (L) or as the 2/+G6P ratio (M). N: Liver glycogen levels.
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in similar increases in blood glucose levels, hepatic PKBb
activity, and phosphorylation of S6K for GYS2+/R582A and
GYS2+/+ (Fig. 5I–K). GYS2 S8 and S641 phosphorylation was
robustly reduced in both genotypes, which was associated
with an increase in GS activity ratio (Fig. 5K–M). Con-
sistent with the data from the glucose injection experi-
ment (Fig. 5C), hepatic glycogen content in response to
refeeding after an overnight fast was significantly lower
in GYS2+/R582A compared with GYS2+/+ animals (Fig. 5N).
Normal hepatic glycogen synthesis in heterozygous
GYS2+/2 knockout mice after glucose administration.
To demonstrate that impaired glycogen resynthesis in
fasted GYS2+/R582A mice was due to insensitivity to G6P
and not the modest reduction in GYS2 expression (as
shown in Fig. 3D and E), we used GYS2+/2 knockout mice,
which have ;50% total GYS2 expression/activity (Fig. 6A
and B) compared with GYS2+/+. Glucose administration
resulted in a similar increase and clearance of blood glu-
cose levels (Supplementary Fig. 8A and B), hepatic PKBb
activity (Supplementary Fig. 8C), and GS activity ratio
(Fig. 6C). Liver glycogen levels were indistinguishable
between GYS2+/2 and control littermate GYS2+/+ animals
after an overnight fast and in response to glucose injection
(Fig. 6D). These results demonstrate that reducing GYS2
protein expression to as low as 50% is not rate limiting
for glycogen synthesis under physiological conditions and
therefore support our conclusion that impaired glycogen
accumulation in GYS2+/R582A mice is due to reduced G6P-
dependent GYS2 activity. However, although the genetic
background for both R582A knockin and GYS2+/2 mice is
the C57BL/6J strain, the results would have been more
compelling if these two lines had been crossed and gly-
cogen accumulation was assessed side by side.
Whole-body insulin sensitivity and glucose homeosta-
sis of GYS2 R582A animals. For determination of the
impact of impaired hepatic glycogen synthesis and altered
glucose flux on whole-body insulin sensitivity, a euglycemic-
hyperinsulinemic clamp was performed. Consistent with
the data from the glucose tolerance test (Fig. 5A), blood
glucose prior to the clamp (6-h fast) was significantly
lower in GYS2R582A/R582A mice. Blood glucose levels were
clamped at ;5.5–6.5 mmol/L for all genotypes through-
out the clamp period (Fig. 7A). Basal plasma insulin
levels were significantly lower in GYS2R582A/R582A com-
pared with GYS2+/+ or GYS2+/R582A mice but normalized
during the clamp (Fig. 7E). Notably, glucose infusion rate
was robustly reduced in GYS2R582A/R582A mice throughout
the clamp period (Fig. 7B), which was associated with a sig-
nificantly reduced rate of glucose disposal and glucose
clearance (Fig. 7C and D). Although endogenous glucose
production was reduced in GYS2R582A/R582A mice in the basal
state, it was suppressed to a similar extent compared with
the other two genotypes during the clamp (Fig. 7C). There
was no significant difference in PKBb activity among geno-
types at the cessation of the clamp (Fig. 7F). There were no
significant differences in clamp measurements between
GYS2+/R582A and GYS2+/+ mice (Fig. 7B–E), which demon-
strates that in the euglycemic-hyperinsulinemic condition,
GYS2+/R582A mice, which display a partial defect in hepatic
glycogen synthesis, have normal whole-body insulin sen-
sitivity. By contrast, insulin sensitivity in GYS2R582A/R582A
mice with a complete absence of hepatic glycogen synthesis
is impaired, although the impairment is modest, as whole-body
Rd was only reduced by ~20% in GYS2R582A/R582A compared
with WT mice during the euglycemic-hyperinsulinemic
clamp.
FIG. 6. Glycogen accumulation and GS activity in GYS21/2 mice after bolus glucose injection. A–D: GYS21/2 and GYS2+/+ mice were fasted for 16 h
followed by administration of saline or glucose (2 mg/g body wt i.p.). *P < 0.05 GYS2+/+ vs. other genotypes (n = 5–7/group). Mice were killed after
30 min and analyzed as follows. A: Liver lysates were immunoblotted using the indicated antibodies. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as a loading control. B and C: GS activity was measured in liver lysates 6 10 mmol/L G6P and is presented as total GS activity
(B) or as the 2/+G6P ratio (C). D: Liver glycogen levels.
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DISCUSSION
In recent years, much of the relevant research has been
directed toward elucidating the regulation and role of
GSK3 and PP1 in the control of GYS2 and hepatic glycogen
synthesis using mouse genetic studies (12–14,16), but the
regulation of GYS2 by G6P has not been studied in vivo
in a mouse model. GSK3a/bS21A/S21A/S9A/S9A knockin animals
display normal glycogen deposition during a euglycemic-
hyperinsulinemic clamp and after refeeding (30). Similarly,
liver glycogen accumulation in PP1-GLY284F/Y284F mice in
response to glucose challenge after overnight fasting is
comparable with that in WT animals in vivo (Supplemen-
tary Fig. 9). Although the constitutive knockin might have
inevitable/secondary adaptive changes that cannot be ad-
equately taken into account, these results raised a possi-
bility of a GSK3- and PP1-GL–independent pathway that
might play a role in regulating hepatic glycogen synthesis
in response to insulin, feeding, and glucose load.
The importance of G6P flux/cycling in hepatic glycogen
synthesis and blood glucose homeostasis is well estab-
lished, and the immediate response of the liver to insulin
or feeding is to redirect G6P derived from gluconeogenesis
and blood glucose to glycogen, thus effectively suppress-
ing glucose output (31,32). Consistent with this, several
studies have shown that changes in [G6P]i correlate with
changes in GYS2 (and also GP) activity and glycogen
content in hepatocytes (8,33). However, there is no com-
pelling evidence that G6P has a direct impact on glycogen
synthesis through modulating GYS2 activity. To this end,
we have used a knockin mouse model (GYS2+/R582A) in
which G6P sensitivity has been profoundly impaired (60–
70%), while sparing regulation by reversible phosphoryla-
tion (Fig. 5H, K, and L), and established that G6P-mediated
activation of GYS2 plays a role in hepatic glycogen syn-
thesis in response to feeding or glucose load in vivo (Fig. 5C
and N). This was further supported by observations in
GYS2-null hepatocytes, where ectopic expression of
R582A GYS2 failed to increase glycogen synthesis in the
presence of high glucose, which was corrected by PP1-
PTG–driven dephosphorylation and activation, albeit to
a lesser extent compared with WT (Fig. 2B and C). The
exact reason why R582A was not activated (with PTG) to
the same level as WT is unclear. Since G6P is thought to
regulate the activity of GYS2 not only by allosteric acti-
vation of the phosphorylated enzyme but also by making
the phosphorylated protein a better substrate for de-
phosphorylation by PP1 (34), it was speculated that R582A
may be less efficiently dephosphorylated by PP1. However,
key regulatory phosphorylation sites (S8 and S641) (27)
were reduced to the same extent between WT and R582A.
Still, S641 phosphorylation was only partially reduced by
PTG overexpression, and we cannot eliminate the possi-
bility that total dephosphorylation (Fig. 2C) would render
R582A fully active. It is also possible that other unchar-
acterized posttranslational modifications (e.g., phosphor-
ylation or acetylation [35,36]) had occurred in R582A and
affected GYS2 activity in intact hepatocytes. Collectively, it
can be concluded that G6P binding to GYS2 has composite
effects in controlling glycogen synthesis through allosteric
activation and efficient dephosphorylation coupled also
with appropriate cellular localization.
The hypomorphic effect in GYS2R582A/R582A mice was
unexpected because R582A expressed normally in HEK293
cells and an identical amino acid substitution in muscle
GS/GYS1 did not display hypomorphism in GYS1R582A/R582A
mice (21). One distinct difference between the two
knockin models is the impact on tissue glycogen levels. In
GYS2R582A/R582A mice, hepatic glycogen content was re-
duced .95% in the fed state compared with WT (Fig.
3H), while muscle glycogen in GYS1R582A/R582A mice was
FIG. 7. Euglycemic-hyperinsulinemic clamp in GYS2+/+, GYS2+/R582A, and GYS2R582A/R582A mice. A–F: GYS2+/+, GYS2+/R582A, and GYS2R582A/R582A mice
ranging from 14 to 18 weeks old were fasted for 6 h prior to clamp. The clamp was performed by the Vanderbilt Mouse Metabolic Phenotyping
Center (Vanderbilt University, Nashville, TN) under conditions described in RESEARCHDESIGNANDMETHODS. *P< 0.05 GYS2+/+ vs. other genotypes (n =
7–8/group). A: Blood glucose levels were measured at indicated time points. B: Glucose infusion rates. C: Glucose flux rates as well as glucose
clearance (D) were determined using [3-3H]glucose. E: Insulin levels were measured after 6 h of fasting (basal) and during the steady-state period
of the clamp. F: Tissue samples were collected after the clamp, and PKBb kinase activity was measured in immunoprecipitates.
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only reduced ;50% compared with WT. Gys2 mRNA
expression was normal in GYS2R582A/R582A mice (Fig.
3F), and the large reduction in G6P-saturated GS activity
(.60–70%) relative to expression (27%) in GYS2+/R582A mice
demonstrates that the mutant allele can be expressed (Fig.
3E and G). The most plausible explanation for the hy-
pomorphism of GYS2R582A/R582A mice is that GYS2 is
unstable or suppressed in the near absence of hepatic
glycogen in these mice. Indeed, the expression of glycogen-
bound proteins examined in GYS2R582A/R582A (e.g., AGL, gly-
cogenin, and GP) (Fig. 3J) and GYS22/2 (Supplementary
Fig. 4) mice was robustly reduced, suggesting that glyco-
gen itself may play an important role for their stability.
There is a genetic disorder known as glycogen storage
disease 0 (GSD0), caused by loss-of-function mutations in
the GYS2 gene, one of few glycogen storage diseases
characterized by reduced levels of hepatic glycogen (4).
Patients present with postprandial hyperglycemia due to
inefficient blood glucose clearance most likely resulting
from inability to store glucose as liver glycogen. This results
in a shift of glucose-G6P flux into glycolytic and lipogenic
pathways leading to hyperlactemia and hyperlipidemia,
respectively. GYS2R582A knockin mice recapitulated GSD0
phenotypes at the whole-body level based on observations
from glucose tolerance tests (Fig. 5A and B) and hyper-
insulinemic-euglycemic clamp (Fig. 7). In addition, at the
cellular level, results from [14C]glucose labeling in primary
hepatocytes from GYS2+/R582A and GYS2R582A/R582A animals
showed a clear shift of glucose-G6P flux toward glycolytic
and lipogenic pathways (Fig. 4B–D).
In summary, we have provided genetic evidence that
G6P-mediated activation of GYS2 plays some role in con-
trolling glycogen synthesis and glucose-G6P flux control,
which affects hepatic glucose, glycogen and lipid metab-
olism, as well as whole-body glucose homeostasis.
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